ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 3| March2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753 || ISI Value: 1.188

FORMULATION AND EVALUATION OF PARACETAMOL TRANSDERMAL FILM BY SOLVENT CASTING METHOD

Deepak Sivaji[1], Durga Chellan [1], Lokesh Saravanan[1], Mageshwari Vengatesan[1]
O. Mullaikodi [1*], V. Kannabirran[1], D. Rajalingam[1]
[1]Department of Pharmaceutics, Kamalakshi Pandurangan College of Pharmacy Tiruvannamalai, Tamilnadu-03, Affiliated with TN Dr. M.G.R. Medical University, Chennai-32.

ABSTRACT
Paracetamol is a widely used analgesic and antipyretic drug with excellent safety at therapeutic doses. However, conventional oral administration suffers from drawbacks such as hepatic first-pass metabolism, short half-life, and the need for frequent dosing. Transdermal drug delivery systems (TDDS) offer controlled drug release, improved bioavailability, and better patient compliance. Due to the hydrophilic nature and low permeability of paracetamol, various formulation strategies such as the use of permeation enhancers, polymeric matrices, nanocarriers, and physical enhancement techniques have been investigated. This review provides a detailed overview of the physicochemical properties of paracetamol, skin structure, formulation components, preparation methods, evaluation parameters, permeation enhancement approaches, recent advancements, and future perspectives in the development of paracetamol transdermal patches.

KEYWORDS: *Paracetamol, Transdermal drug delivery system, Permeation enhancer, Controlled release, Franz diffusion cell.*

1. INTRODUCTION

Paracetamol (acetaminophen) is one of the most frequently used non-opioid analgesic and antipyretic agents for the management of mild to moderate pain and fever. It is widely preferred in clinical practice due to its favorable safety profile, minimal gastrointestinal irritation, and good patient tolerability compared with non-steroidal anti-inflammatory drugs. However, conventional oral administration of paracetamol is associated with certain limitations, including extensive first-pass hepatic metabolism, short biological half-life, and the requirement for repeated dosing to maintain effective plasma drug concentration. These factors may lead to fluctuations in drug levels, reduced patient compliance, and an increased risk of dose-related hepatotoxicity in cases of prolonged or excessive use.

Transdermal drug delivery systems have emerged as a promising alternative for the systemic administration of drugs, offering controlled and sustained release, avoidance of gastrointestinal degradation, and improved bioavailability by bypassing hepatic first-pass metabolism. In addition, this route enhances patient convenience and allows termination of therapy by simple removal of the patch. Despite these advantages, the development of a transdermal formulation for paracetamol presents a significant challenge due to its hydrophilic nature and limited ability to permeate the stratum corneum, the primary barrier of the skin. Therefore, the successful design of paracetamol transdermal patches requires the use of suitable polymers, plasticizers, and permeation enhancement strategies to facilitate drug transport across the skin. The present review focuses on the formulation approaches, evaluation methods, and recent advances in the development of paracetamol transdermal patches as an alternative to conventional dosage forms.

2. PHYSICOCHEMICAL AND BIOLOGICAL PROFILE OF PARACETAMOL

2.1 Physicochemical Properties

Paracetamol (acetaminophen) is chemically designated as N-(4-hydroxyphenyl) acetamide and is a low molecular weight compound with a value of approximately 151.16 g/mol. It appears as a white, crystalline, odorless powder with a slightly bitter taste. The drug exhibits a melting point in the range of 168–172 °C, indicating its crystalline and thermally stable nature. Paracetamol is sparingly soluble in water but shows higher solubility in organic solvents such as ethanol, methanol, and acetone. The aqueous solubility of paracetamol increases with temperature and pH, which plays an important role in formulation development.

From a stability perspective, paracetamol is relatively stable under normal conditions but may undergo hydrolysis and oxidation in the presence of moisture, light, and oxidizing agents. Therefore, appropriate selection of excipients, packaging materials, and storage conditions is essential during the formulation of transdermal patches.

2.2 Biological and Pharmacokinetic Properties

Paracetamol is widely used for its analgesic and antipyretic activity. The analgesic effect is primarily mediated through inhibition of prostaglandin synthesis in the central nervous system and modulation of serotonergic pathways involved in pain perception. The antipyretic action results from its effect on the hypothalamic heat-regulating center, leading to peripheral vasodilation and increased heat dissipation.

After oral administration, paracetamol is rapidly and almost completely absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 30–60 minutes. However, its oral bioavailability ranges between 60 % and 80 % due to significant first-pass metabolism in the liver. The drug

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 3| March2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753 || ISI Value: 1.188

is widely distributed throughout body fluids, with a relatively low plasma protein binding of about 10–25 % at therapeutic concentrations.

The elimination half-life of paracetamol is approximately 2–3 hours in healthy individuals, which necessitates frequent dosing in conventional therapy. The metabolites are primarily excreted through the kidneys. The short half-life and the need for repeated administration make paracetamol a suitable candidate for controlled and sustained drug delivery systems such as transdermal patches.

2.3 Suitability of Paracetamol for Transdermal Drug Delivery

The biological half-life, low molecular weight, and relatively low dose requirement favor the development of a transdermal therapeutic system. In addition, the extensive first-pass metabolism associated with oral delivery can be avoided by transdermal administration, thereby improving systemic availability. However, the hydrophilic nature and low partition coefficient of paracetamol limit its ability to permeate through the stratum corneum. Hence, the formulation of an effective transdermal system requires the incorporation of suitable polymers, plasticizers, and permeation enhancers to achieve the desired drug flux.

3. RATIONALE FOR TRANSDERMAL DELIVERY OF PARACETAMOL

Paracetamol is widely administered by the oral route; however, it undergoes extensive first-pass hepatic metabolism and has a short biological half-life, which necessitates frequent dosing to maintain therapeutic drug levels. This results in fluctuating plasma concentrations, reduced patient compliance, and an increased risk of dose-related hepatotoxicity during prolonged therapy. Transdermal drug delivery offers an effective alternative by bypassing the gastrointestinal tract and hepatic first-pass effect, thereby improving systemic availability and maintaining a constant plasma drug concentration for an extended period.

In addition, transdermal patches provide several clinical advantages such as non-invasive administration, ease of application, improved patient adherence, and the possibility of immediate termination of therapy by simple patch removal. Paracetamol possesses a low molecular weight and is effective at relatively low doses, which are favorable characteristics for controlled drug delivery. However, its hydrophilic nature limits passive permeation through the stratum corneum, making the use of suitable polymers and permeation enhancement strategies essential. Therefore, the development of a transdermal therapeutic system for paracetamol represents a rational approach to achieve sustained drug release, reduced dosing frequency, and improved therapeutic efficacy.

4. SKIN AS A SITE FOR DRUG DELIVERY

The skin is the largest organ of the human body, covering a surface area of approximately 1.5–2.0 m² in adults, and serves as a protective barrier against environmental, chemical, and microbial insults. In addition to its physiological functions such as thermoregulation, sensory perception, and prevention of water loss, the skin has gained considerable importance as a potential route for systemic drug delivery. The transdermal route utilizes the skin as a portal for the absorption of therapeutic agents into the systemic circulation, thereby providing controlled and sustained drug release.

4.1 Structure of the Skin

Anatomically, the skin is composed of three main layers: the epidermis, dermis, and hypodermis.

Epidermis

The epidermis is the outermost layer of the skin and is primarily responsible for its barrier properties. It is a stratified, avascular epithelium consisting of several sublayers, namely the stratum basale, stratum spinosum, stratum granulosum, stratum lucidum (in thick skin), and the stratum corneum. Among these, the stratum corneum plays a crucial role in controlling drug permeation. It is composed of dead, flattened keratinized cells embedded in a lipid matrix, often described by the “brick and mortar” model, where corneocytes act as the bricks and intercellular lipids function as the mortar. This highly organized structure restricts the entry of most hydrophilic and high molecular weight substances.

Dermis

The dermis lies beneath the epidermis and is a connective tissue layer rich in collagen and elastin fibers. It contains blood vessels, lymphatics, nerves, hair follicles, and sweat glands. Once a drug molecule crosses the epidermal barrier and reaches the dermis, it can be readily absorbed into the systemic circulation through the extensive vascular network present in this layer.

Hypodermis (Subcutaneous tissue):

The hypodermis is the innermost layer composed mainly of adipose tissue. It provides mechanical support, thermal insulation, and flexibility to the skin. Although it does not directly act as a barrier to drug permeation, it influences the overall disposition of the drug after absorption.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 3| March2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753 || ISI Value: 1.188




Fig no.1 Structure of the Skin

4.2 Pathways of Drug Permeation through the Skin

Drugs can penetrate the skin by three principal pathways:

Transcellular (Intracellular) Route

The drug passes directly through the corneocytes. This pathway involves repeated partitioning between the hydrophilic and lipophilic domains of the cell membrane.

Intercellular Route

The drug diffuses through the lipid matrix surrounding the corneocytes. This is considered the most common pathway for many drugs.

Appendageal Route

Drug permeation occurs through skin appendages such as hair follicles and sweat glands. Although this route represents a small fraction of the total skin surface area, it can contribute significantly to the absorption of certain molecules, especially ions and polar compounds.

5. COMPONENTS OF TRANSDERMAL PATCH

A transdermal patch is a multilayered drug delivery system in which each component plays a specific role in controlling drug release, maintaining the integrity of the formulation, and ensuring effective permeation through the skin. The design and performance of the patch depend on the proper selection and optimization of its individual components.

5.1 Drug (Active Pharmaceutical Ingredient)

The drug is the key component responsible for the therapeutic activity of the transdermal system. For successful transdermal delivery, the drug should possess certain physicochemical and biological properties such as low molecular weight, high potency, short biological half-life, and adequate solubility in both aqueous and lipid media. Paracetamol is considered a suitable candidate for controlled drug delivery because of its low molecular weight and short half-life, which require frequent administration in conventional dosage forms. However, its hydrophilic nature and low partition coefficient limit its passive diffusion through the stratum corneum, necessitating the use of permeation enhancement techniques in the formulation.

5.2 Polymer Matrix

The polymer matrix forms the structural framework of the transdermal patch and controls the rate and extent of drug release. It provides mechanical strength, flexibility, and uniform distribution of the drug throughout the system. An ideal polymer should be non-toxic, non-irritant, chemically stable, and compatible with the drug and other excipients.

Polymers used in transdermal patches are broadly classified into:

Hydrophilic Polymers

- Hydroxypropyl methylcellulose (HPMC)
- Polyvinylpyrrolidone (PVP)
- Polyvinyl alcohol (PVA)

These polymers absorb moisture, swell, and facilitate faster drug release.

Hydrophobic Polymers

- Ethyl cellulose
- Eudragit
- Cellulose acetate

5.3 Permeation Enhancers

Permeation enhancers are incorporated to increase the permeability of the drug through the stratum corneum and improve transdermal flux. They act by disrupting the ordered structure of skin lipids, increasing drug solubility within the skin, or enhancing the partitioning of the drug into the skin.

An ideal permeation enhancer should be:

- Non-toxic and non-irritant
- Pharmacologically inert
- Effective at low concentration
- Compatible with other formulation components

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 3| March2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753 || ISI Value: 1.188

Common permeation enhancers include:

- Oleic acid
- Isopropyl myristate
- Menthol
- Propylene glycol
- Dimethyl sulfoxide (DMSO)
- Tween 80

5.4 Plasticizers

Plasticizers are added to improve the flexibility, elasticity, and mechanical strength of the polymeric film. They reduce brittleness and prevent cracking of the patch during handling and application. Plasticizers also influence the drug release rate by modifying the internal structure and permeability of the polymer matrix.

Commonly used plasticizers

- Polyethylene glycol (PEG 400)
- Propylene glycol
- Glycerol
- Dibutyl phthalate

5.5 Other excipients

a) Adhesives

The fastening of all transdermal devices to the skin has so far been done by using a pressure sensitive adhesive which can be positioned on the face of the device or in the back of the device and extending peripherally. Both adhesive systems should fulfill the following criteria:

- Should adhere to the skin aggressively, should be easily removed.
- Should not leave an unwashable residue on the skin.
- Should not irritate or sensitize the skin.

The face adhesive system should also fulfill the following criteria.

- Physical and chemical compatibility with the drug, excipients and enhancers of the device of which it is a part.
- Permeation of drug should not be affected.
- The delivery of simple or blended permeation enhancers should not be affected.

b) Backing Membrane

Backing membranes are flexible and they provide a good bond to the drug reservoir, prevent drug from leaving the dosage form through the top, and accept printing. It is impermeable that protects the product during use on the skin e.g. metallic plastic laminate, plastic backing with absorbent pad and occlusive base plate (aluminium foil), adhesive foam pad (flexible polyurethane) with occlusive base plate (aluminium foil disc) etc.

6. METHODS OF PREPARATION OF TRANSDERMAL PATCHES

The method employed for the preparation of transdermal patches plays a crucial role in determining the uniformity of drug distribution, mechanical strength, drug release characteristics, and overall therapeutic performance of the system. Various techniques have been developed for the fabrication of matrix-type and reservoir-type patches. The selection of a suitable method depends on the physicochemical properties of paracetamol, the nature of polymers, and the desired release profile.

6.1 Solvent Casting Method

The solvent casting technique is the most widely used method for the preparation of matrix-type transdermal patches due to its simplicity, reproducibility, and cost-effectiveness.

In this method, accurately weighed quantities of polymer(s) are dissolved in an appropriate volatile solvent such as chloroform, methanol, ethanol, or a mixture of solvents. Paracetamol is then dissolved or dispersed in the polymeric solution under continuous stirring to obtain a uniform drug–polymer mixture. Plasticizers such as polyethylene glycol, propylene glycol, or dibutyl phthalate are incorporated to enhance the flexibility and mechanical strength of the film. Permeation enhancers may also be added to improve drug diffusion through the skin.

The resulting homogeneous solution is poured into a leveled glass mould or petri dish and allowed to dry at controlled temperature to facilitate solvent evaporation. After complete drying, the formed film is carefully removed and cut into patches of desired size and shape.

Advantages

- Uniform drug distribution
- Smooth and flexible films
- Simple and economical method



Fig no 2. Prepared Transdermal patch of paracetamol

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 3| March2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753 || ISI Value: 1.188

7. EVALUATION PARAMETERS OF PARACETAMOL TRANSDERMAL PATCHES

The development of an effective transdermal therapeutic system requires comprehensive evaluation to ensure its physicochemical stability, mechanical integrity, drug release performance, and skin compatibility. In the case of paracetamol transdermal patches, these evaluation parameters are particularly important because the drug possesses moderate aqueous solubility and limited skin permeability. Therefore, systematic characterization is essential for optimizing formulation variables and achieving reproducible therapeutic outcomes.

7.1 Physicochemical Properties

Physicochemical evaluation provides preliminary information regarding the uniformity and stability of the prepared patches. Visual inspection is commonly performed to assess transparency, smoothness, flexibility, and the presence of air bubbles or drug crystallization. A uniform and homogeneous appearance generally indicates good compatibility between the drug and the polymeric matrix.

Thickness and weight variation are measured to confirm the reproducibility of the casting process and uniform distribution of the drug throughout the film. These parameters are directly related to dose accuracy and drug release behavior. Moisture content and moisture uptake studies are also carried out to evaluate the influence of environmental humidity on the formulation. Excessive moisture absorption may affect the mechanical strength and promote microbial growth, whereas extremely low moisture levels can lead to brittleness.

Drug content uniformity is a critical quality control parameter for transdermal systems. It ensures that the drug is evenly distributed within the polymer matrix and that each patch delivers the intended dose. Spectrophotometric and chromatographic methods are widely used for quantitative analysis. Surface pH is determined to predict the potential for skin irritation, and formulations with a pH close to that of the skin are considered suitable for prolonged application.

7.2 Mechanical Properties

Mechanical properties play a significant role in maintaining the structural integrity of transdermal patches during storage, handling, and application. Folding endurance reflects the flexibility and resistance of the patch to mechanical stress. High folding endurance values are generally associated with the presence of an appropriate plasticizer, which reduces intermolecular forces within the polymer network.

Tensile strength and percentage elongation at break are important indicators of the mechanical performance of the film. These parameters help in determining whether the patch can withstand external stress without breaking while maintaining sufficient elasticity for proper skin adherence. An optimal balance between strength and flexibility is essential for patient convenience and product durability.

7.3 Skin Irritation and Stability Studies

Skin irritation studies are essential to evaluate the safety of transdermal patches for topical application. A formulation intended for prolonged contact with the skin must be non-irritant and well tolerated. These studies are usually performed on animal models to observe any signs of erythema or edema.

Stability studies are conducted under different temperature and humidity conditions to assess changes in physical appearance, drug content, mechanical properties, and release characteristics over time. These studies are crucial for predicting the shelf life of the formulation and establishing appropriate storage conditions.

8. KINETIC MODELING OF DRUG RELEASE FROM PARACETAMOL TRANSDERMAL PATCHES

Kinetic modeling is widely applied to evaluate the mechanism and rate of drug release from paracetamol transdermal patches and to assess their ability to provide sustained therapeutic action. By fitting in-vitro release data into various mathematical models, the influence of polymer composition, drug loading, and formulation additives on the release profile can be clearly understood. This approach also helps in predicting in-vivo performance and in comparing different formulations during the development stage.

Among the different models, the Higuchi model is most commonly followed by matrix-type transdermal systems, indicating that drug release occurs predominantly by diffusion through the hydrated polymeric network. Zero-order kinetics, which represents a constant drug release independent of concentration, is considered ideal for maintaining uniform plasma drug levels, although it is rarely achieved in conventional matrix films. The Korsmeyer–Peppas model is frequently used to further interpret the release mechanism, and the release exponent (n value) for paracetamol patches generally indicates anomalous or non-Fickian transport. This suggests that both drug diffusion and polymer relaxation or swelling contribute to the overall release process.

9. ADVANTAGES OF PARACETAMOL TRANSDERMAL PATCH

The transdermal delivery of paracetamol offers several therapeutic and pharmaceutical advantages over conventional oral and parenteral dosage forms. These benefits are primarily related to improved drug release control, enhanced patient compliance, and reduction of systemic side effects. In recent years, the development of paracetamol transdermal patches has gained considerable attention as an alternative approach for prolonged analgesic and antipyretic therapy.

One of the major advantages of the transdermal system is the ability to provide controlled and sustained drug release over an extended period. This helps in maintaining relatively constant plasma drug concentrations and reduces the fluctuations associated with repeated oral dosing. As paracetamol has a short biological half-life and requires frequent administration, the transdermal route can significantly decrease dosing frequency and improve therapeutic efficacy.

Transdermal delivery also bypasses the hepatic first-pass metabolism, which can enhance the bioavailability of the drug.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 3| March2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753 || ISI Value: 1.188

In addition, it minimizes gastrointestinal irritation, a common drawback associated with oral administration, making it a suitable option for patients with gastric sensitivity or those who are unable to take medications orally.

Another important advantage is improved patient compliance, especially in pediatric, geriatric, and unconscious patients, as the patch is non-invasive, painless, and easy to apply and remove. The system also allows for termination of therapy at any time by simply removing the patch, which is not possible with sustained-release oral formulations.

Furthermore, transdermal patches provide uniform drug delivery, reduce the risk of dose dumping, and can be designed to deliver the drug for prolonged durations. They also avoid fluctuations in plasma drug levels, thereby reducing the chances of dose-related adverse effects, particularly hepatotoxicity associated with high oral doses of paracetamol.

From a pharmaceutical perspective, these systems offer better stability, convenience in use, and improved therapeutic control. Overall, the paracetamol transdermal patch represents a promising drug delivery strategy for achieving sustained analgesic and antipyretic action with enhanced safety and patient acceptability.

10. LIMITATIONS

Although transdermal delivery of paracetamol offers several therapeutic benefits, its development is associated with a number of limitations. The primary challenge arises from the poor permeability of paracetamol across the stratum corneum, as the drug possesses moderate hydrophilicity and limited lipophilicity. This restricts its passive diffusion through the skin and often necessitates the use of permeation enhancers, which may cause skin irritation or sensitization on prolonged application.

Another important limitation is the requirement of a relatively high therapeutic dose. Transdermal systems are generally suitable for potent drugs administered in small quantities, and delivering an adequate amount of paracetamol through the skin remains a formulation challenge due to limited drug loading capacity.

In addition, inter-individual variability in skin permeability, influenced by factors such as age, hydration, and site of application, can lead to differences in drug absorption and therapeutic response. The complexity of formulation design and higher production cost also restrict the large-scale commercialization of these systems.

Overall, these constraints highlight the need for careful selection of polymers, permeation enhancement strategies, and optimization of drug release to achieve clinically effective paracetamol transdermal patches.

11. FUTURE PROSPECTS

The future of paracetamol transdermal delivery is closely linked to advances in polymer science, skin permeation technologies, and novel formulation strategies aimed at overcoming the inherent barrier properties of the stratum corneum. Although conventional matrix patches have demonstrated controlled drug release, further enhancement in transdermal flux is required to achieve therapeutically effective plasma concentrations. Emerging approaches such as the use of nanocarriers, microemulsions, lipid-based vesicular systems, and drug–polymer hybrid networks are expected to significantly improve the permeation profile of paracetamol through the skin.

The incorporation of novel permeation enhancement techniques, including microneedles, iontophoresis, sonophoresis, and electroporation, represents a promising direction for increasing drug transport without causing significant skin irritation. These physical enhancement methods can temporarily disrupt the stratum corneum, thereby facilitating the delivery of drugs with suboptimal physicochemical properties for passive diffusion.

Another important area of development is the design of stimuli-responsive and rate-controlled transdermal systems, which can modulate drug release in response to physiological conditions such as temperature, pH, or external triggers. Such systems may offer improved therapeutic control and personalized drug delivery.

In addition, the integration of transdermal patches with smart wearable technologies for real-time monitoring of drug release and patient compliance is gaining increasing attention. This approach could be particularly beneficial in chronic pain management, where sustained and controlled delivery of paracetamol is required.

12. CONCLUSION

Paracetamol transdermal patches represent a promising alternative to conventional oral dosage forms for achieving prolonged analgesic and antipyretic action. By providing controlled and sustained drug release, these systems help to maintain uniform plasma drug levels, reduce dosing frequency, and improve patient compliance. The selection of suitable polymers, plasticizers, and permeation enhancers plays a crucial role in determining the performance of the formulation, and most reported systems exhibit diffusion-controlled release with anomalous transport behavior.

However, limitations such as low skin permeability, dose requirements, and the possibility of skin irritation remain key challenges in their development. Recent advances in permeation enhancement techniques and novel drug delivery approaches are expected to improve the transdermal flux of paracetamol and enhance its clinical applicability.

In conclusion, with further optimization and in-vivo correlation studies, paracetamol transdermal patches have significant potential to serve as an effective and patient-friendly controlled drug delivery system for the management of pain and fever.

REFERENCES

1. *Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268.*

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 3| March2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753 || ISI Value: 1.188

2. *Hadgraft J, Guy RH. Transdermal drug delivery: Developmental issues and research initiatives. Marcel Dekker; 2003.*
3. *Barry BW. Breaching the skin's barrier to drugs. Nat Biotechnol. 2004;22(2):165–167.*
4. *Benson HAE. Transdermal drug delivery: Penetration enhancement techniques. Curr Drug Deliv. 2005;2(1):23–33.*
5. *Guy RH. Current status and future prospects of transdermal drug delivery. Pharm Res. 1996;13(12):1765–1769.*
6. *Dhiman S, Thakur GS, Rehni AK. Transdermal patches: A recent approach to new drug delivery system. Int J Pharm Pharm Sci. 2011;3(5):26–34.*
7. *Mutalik S, Udupa N. Formulation development, in vitro and in vivo evaluation of transdermal patches of glibenclamide. J Pharm Pharm Sci. 2004;7(2):157–162.*
8. *Aqil M, Ali A. Monolithic matrix type transdermal drug delivery systems of pinacidil monohydrate: In vitro characterization. Eur J Pharm Biopharm. 2003;54(2):161–164.*
9. *Chien YW. Novel drug delivery systems. 2nd ed. Marcel Dekker; 1992.*
10. *Patel RP, Patel G, Baria AH. Formulation and evaluation of transdermal patch of aceclofenac. Int J Drug Deliv. 2009;1(1):41–51.*
11. *Kulkarni RV, Mutalik S. Effect of plasticizers on the permeability and mechanical properties of eudragit films for transdermal application. Indian J Pharm Sci. 2002;64(1):28–31.*
12. *Moghadam SH, Saliaj E, Wettig SD, Dong C, Ivanova MV, Huzil JT, Foldvari M. Effect of chemical permeation enhancers on stratum corneum barrier lipid organizational structure and interferon alpha permeability. Mol Pharm. 2013;10(6):2248–2260.*
13. *Jain NK. Controlled and novel drug delivery. 1st ed. CBS Publishers & Distributors; 2008.*
14. *Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dale's pharmacology. 8th ed. Elsevier; 2016.*
15. *Sweetman SC. Martindale: The complete drug reference. 36th ed. Pharmaceutical Press; 2009.*
16. *Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2012;64:128–137.*
17. *Trommer H, Neubert RHH. Overcoming the stratum corneum: The modulation of skin penetration. Skin Pharmacol Physiol. 2006;19(2):106–121.*
18. *Patel D, Chaudhary SA, Parmar B, Bhura N. Transdermal drug delivery system: A review. Pharm Innov. 2012;1(4):66–75.*
19. *Ubaidulla U, Reddy MV, Ruckmani K, Ahmad FJ, Khar RK. Transdermal therapeutic system of carvedilol: Effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics. AAPS PharmSciTech. 2007;8(1):E1–E8.*
20. *ICH Harmonised Tripartite Guideline. Stability testing of new drug substances and products Q1A(R2). International Conference on Harmonisation; 2003.*
21. *Gupta R, Mukherjee B. Development and in vitro evaluation of diltiazem hydrochloride transdermal patches based on povidone–ethyl cellulose matrices. Drug Dev Ind Pharm. 2003;29(1):1–7.*
22. *Arora P, Mukherjee B. Design, development, physicochemical, and in vitro and in vivo evaluation of transdermal patches containing diclofenac diethylammonium. J Pharm Sci. 2002;91(9):2076–2089.*
23. *Cilurzo F, Minghetti P, Casiraghi A, Montanari L. Design of a new transdermal system for ketoprofen: In vitro and in vivo evaluation. Eur J Pharm Biopharm. 2005;59(3):473–478.*
24. *Guy RH, Hadgraft J. Physicochemical aspects of percutaneous penetration and its enhancement. Pharm Res. 1988;5(12):753–758.*
25. *Kanikkannan N. Technologies to improve the transdermal delivery of drugs. Expert Opin Drug Deliv. 2002;1(1):1–13.*
26. *Williams AC. Transdermal and topical drug delivery: From theory to clinical practice. Pharm Press; 2003.*
27. *Flynn GL. Physicochemical determinants of skin absorption. In: Principles of route-to-route extrapolation for risk assessment. Elsevier; 1990. P. 93–127.*
28. *Potts RO, Guy RH. Predicting skin permeability. Pharm Res. 1992;9(5):663–669.*